Phase I Trial of Intravenous Recombinant Human TNF-alpha and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2015
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Tumour necrosis factor alpha (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 15 Jun 2015 Status changed from suspended to withdrawn prior to enrolment as per ClinicalTrials.gov.
- 16 Apr 2013 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 19 Sep 2012 Planned initiation date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.